Abstract: Objective The aim of this study was to investigate the s short-term efficacy of polyene phosphatidylcholine combined with metformin and fenofibrate in patients with nonalcoholic fatty liver disease (NAFLD). Methods 64 patients with NAFLD were recruited in our hospital between March 2015 and June 2019, and were randomly divided into control (n=32) and observation group (n=32). The patients in the control group were treated orally with metformin and fenofibrate capsules, while those in the observation group were additionally treated with polyene phosphatidylcholine capsules at the base of medicine mentioned above. The observation lasted for 12 weeks. Serum hyaluronic acid (HA), laminin (LN), high mobility group protein (HMGB1) and interleukin -17 (IL-17) were detected.Results At the end of 12 week observation, blood triglyceride (TG) level was (1.8±0.1)mmol/L, significantly lower than 【(2.7±0.4)mmol/L, P＜0.05】, total cholesterol (TC) level was (4.6±0.4)mmol/L, significantly lower than 【(5.8±0.6)mmol/L, P＜0.05】, while blood high density lipoprotein cholesterol (HDL-C) level was(1.9±0.5)mmol/L, significantly higher than 【(1.5±0.4)mmol/L, P＜0.05】 in the control; serum ALT level was (28.4±3.2)U/L, much lower than 【(35.9±4.1)U/L, P＜0.05】, AST level was (22.1±2.0)U/L, much lower than 【(32.6±3.4)U/L, P＜0.05】, serum HMGB1 level was (13.7±1.5)μg/L, significantly lower than 【(20.2±2.4)μg/L, P＜0.05】, and serum IL-17 level was (75.6±7.8)pg/mL, significantly lower than 【(90.7±10.2)pg/mL, P＜0.05】 in the control group; serum HA level was (84.5±9.2)mg/L, significantly lower than 【(117.6±10.3)mg/L, P＜0.05】, LN level was (91.2±10.2)μg/L, significantly lower than 【(108.7±11.3)μg/L, P＜0.05】, and serum Pygo2 level was (37.5±4.1)μg/L, much lower than 【(42.4±5.0)μg/L, P＜0.05】 in the control. Conclusion The administration of polyene phosphatidylcholine combined with metformin and fenofibrate tablets might obviously improve blood lipid metabolism and inhibit inflammatory reactions in patients with NAFLD, which needs long-term investigation.

Key words: Non-alcoholic fatty liver diseases, Polyene phosphatidylcholine, Metformin, Fenofibrate, Human tail limb homologous protein 2, Therapy